OKYO — OKYO Pharma Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1849296 ·
Last close
$1.69
Market Cap
$88.69M
52W High
$1.85
52W Low
$1.42
ADV30
85,639
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | — | — | — | — | 4,643,837 | 4,220,378 | 8,059,143 |
| Mar 2025 | — | — | — | — | 3,677,336 | 1,560,902 | 9,226,891 |
| Sep 2024 | — | — | — | — | 2,828,858 | 987,199 | 10,054,490 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,608,778
Inventory
—
Receivables
$23,414
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 0 | -7,091,897 | -4,706,292 | 3,677,336 | 9,226,891 | — | -1,810,931 |
| Mar 2024 | 0 | -15,749,732 | -16,825,461 | 1,541,264 | 7,420,846 | — | -9,490,537 |
| Mar 2023 | 0 | -13,187,200 | -13,271,685 | 5,203,920 | 7,257,157 | — | -7,695,242 |
| Mar 2022 | 0 | -6,217,566 | -5,431,045 | 4,300,593 | 1,353,191 | — | -5,468,065 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $87.94M | $9.76 | — |
| LONA | LeonaBio, Inc. | $90.18M | $9.60 | — |
| CRDF | Cardiff Oncology, Inc. | $90.93M | $1.33 | — |
| PTHS | Pelthos Therapeutics Inc. | $92.28M | $26.55 | — |
| ENTX | Entera Bio Ltd. | $81.58M | $1.65 | — |
News headlines (Yahoo Finance, 1h cache)
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain
2026-07-08 12:33 · Yahoo
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
2026-07-08 11:00 · Yahoo
OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain
2026-07-07 15:18 · Yahoo
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
2026-07-07 11:00 · Yahoo
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
2026-05-23 12:00 · Yahoo
What Makes OKYO Pharma (OKYO) a New Buy Stock
2026-05-20 16:00 · Yahoo
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
2026-05-19 15:02 · Yahoo
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
2026-05-19 13:58 · Yahoo
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
2026-05-19 11:00 · Yahoo
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
2026-04-29 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.